Targeting the Untargeted
Making metastasis a druggable frontier
O₂nix Bio is developing pro-oxidant therapeutics that exploit oxidative stress liabilities in metastatic and therapy-resistant cancer.
What We Do
The Problem
Metastasis drives most cancer deaths, yet remains under-targeted by current therapies.
Our Insight
Metastatic progression creates heightened oxidative stress dependencies.
Our Approach
Pro-oxidant therapeutics designed to exploit oxidative stress liabilities in metastatic cells.
Who We Are
O₂nix Bio is an oncology therapeutics company developing pro-oxidant medicines designed to exploit oxidative stress vulnerabilities in metastatic cancer. Based in Boston (founded 2025), we are advancing a pipeline aimed at selectively targeting metastatic cells and enabling differentiated combination strategies.